– FDA cleared MindMed’s Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120 – – Progressed development programs for all three lead product candidates – – Cash balance of $133.5 million at year end 2021 – – Company to host earnings conference call today at 8:30 AM EDT – NEW YORK, March 28, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED)…


Previous articleMindMed Announces Transition of CFO
Next articlePT305 – Emma Farrell – Plant Spirits, Entities, and Remembering Lost Traditions